Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Palliative Medicine
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Neville-Webbe, H L
Right arrow Articles by Coleman, R E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neville-Webbe, H L
Right arrow Articles by Coleman, R E
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia

H L Neville-Webbe

R E Coleman

Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield

Zoledronic acid is a potent, third generation, nitrogen-containing bisphosphonate, licensed for the management of skeletal metastases and hypercalcaemia of malignancy, both of which cause considerable morbidity. In the preclinical setting, zoledronic acid has demonstrated superior potency regarding inhibition of osteolysis and reduction of hypercalcaemia as compared with other bisphosphonates. Clinical trials have indicated that zoledronic acid is superior to pamidronate in suppressing osteolysis and in reducing hypercalcaemia of malignancy. Its main mechanism of action is induction of osteoclast apoptosis through inhibition of the mevalonate pathway. Zoledronic acid has also demonstrated direct anti-tumour activity both in vitro and in animal models, suggesting it may be of benefit in preventing the formation of bone metastases. Clinical trials are in progress, assessing the benefit of zoledronic acid in the adjuvant setting in both breast and prostate cancer.

Key Words: bisphosphonates • hypercalcaemia • metastatic bone disease • zoledronic acid

Palliative Medicine, Vol. 17, No. 6, 539-553 (2003)
DOI: 10.1191/0269216303pm800ra
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JDRHome page
J.B. Epstein, S. Elad, E. Eliav, R. Jurevic, and R. Benoliel
Orofacial Pain in Cancer: Part II--Clinical Perspectives and Management
Journal of Dental Research, June 1, 2007; 86(6): 506 - 518.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Goblirsch, P. P. Zwolak, and D. R. Clohisy
Biology of bone cancer pain.
Clin. Cancer Res., October 15, 2006; 12(20): 6231s - 6235s.
[Abstract] [Full Text] [PDF]

Home page
 Palliat MedHome page
C. Urch
The pathophysiology of cancer-induced bone pain: current understanding
Palliative Medicine, June 1, 2004; 18(4): 267 - 274.
[Abstract] [PDF]